Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 15;37(4):296-302.
doi: 10.2337/dsi24-0003. eCollection 2024 Fall.

First-Generation Anti-Obesity Medications

Sarah R Barenbaum  1 , Mohini Aras  1
Affiliations

First-Generation Anti-Obesity Medications

Sarah R Barenbaum et al. Diabetes Spectr. .

Abstract

The development of second-generation anti-obesity medications (AOMs) has transformed the treatment of obesity. However, the first-generation AOMs are still essential tools in the treatment of obesity. The decision of which AOM to initiate must be individualized taking into account patient preference, safety, tolerability, cost, and supply.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest relevant to this article were reported.

References

    1. Apovian CM, Aronne LJ, Bessesen DH, et al.; Endocrine Society . Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100:342–362 - PubMed
    1. Garvey WT. New horizons: a new paradigm for treating to target with second-generation obesity medications. J Clin Endocrinol Metab 2022;107:e1339–e1347 - PMC - PubMed
    1. Garvey WT, Mechanick JI, Brett EM, et al.; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines . American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 2016;22(Suppl. 3):1–203 - PubMed
    1. Roche Pharmaceuticals. Xenical [package insert] . Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020766s026lbl.pdf. Accessed March 2024
    1. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L.. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–161 - PubMed